News & Events

Simpson Thacher recently provided IP diligence and advice to Goldman Sachs & Co. in connection with a $40 million round of financing for T2 Biosystems, Inc.  Goldman Sachs led the round as a new investor, and was joined by existing investors Flagship Ventures, Polaris Partners, Aisling Capital, Flybridge Capital Partners, Physic Ventures, Arcus Ventures, Partners Healthcare, Camros Capital and WS Investments.  The financing will support the clinical programs and commercialization of T2Candida™, the Company’s flagship molecular diagnostic test panel for the sensitive and rapid identification of species-specific Candida fungal infections directly from whole blood.

T2 Biosystems is a biotechnology company focused on magnetic resonance-based clinical diagnostics. The Company’s proprietary T2MR technology detects any molecular or immunoassay target or provide broad hemostasis measurements directly from unpurified clinical samples in hospitals, labs and physicians’ offices.

The Simpson Thacher team for this transaction included Noah Leibowitz and Brian McCloskey.